Product Information
TRIMETHOBENZAMIDE 300 MG CAP is a generic product labeled by Chartwell RX LLC, priced at $17.9997 per EA under NDC 62135077330. Its NADAC has been published 66 times since May 21, 2025.
FDA first approved this application on Nov 21, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Chartwell RX LLCNDC
62135077330
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/17/2025
Active Ingredients
TRIMETHOBENZAMIDE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205950FDA Approved
11/21/2023
TE Code
AB
On Market Since
11/21/2023
Pharmacological Classes
Price Statistics
The NADAC for TRIMETHOBENZAMIDE 300 MG CAP has been published 66 times since May 21, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.9997 per EA |
|---|---|
| All-time high | $17.9997 (Aug 19, 2026) |
| All-time low | $17.9997 (May 21, 2025) |
| 52-week high | $17.9997 |
| 52-week low | $17.9997 |
| Median price | $17.9997 |
| Average price | $17.9997 |
| Largest weekly change | 0.0% (May 28, 2025) |
| Weeks tracked | 66 |
| Tracking since | May 21, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 93% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRIMETHOBENZAMIDE 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for TRIMETHOBENZAMIDE 300 MG CAP, manufactured by Chartwell RX LLC, is $17.9997 per EA (NDC 62135077330), effective Aug 19, 2026.
How has the price of TRIMETHOBENZAMIDE 300 MG CAP changed over time?
Over the history we have for it, the NADAC for TRIMETHOBENZAMIDE 300 MG CAP has held within roughly two percent of its current level. It has been tracked across 66 weekly CMS publications since May 21, 2025.
What are the highest and lowest recorded NADAC prices for TRIMETHOBENZAMIDE 300 MG CAP?
Since May 21, 2025, the NADAC for TRIMETHOBENZAMIDE 300 MG CAP has ranged from a low of $17.9997 (May 21, 2025) to a high of $17.9997 (Aug 19, 2026), with a median of $17.9997 per EA.
Are there cheaper alternatives to TRIMETHOBENZAMIDE 300 MG CAP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRIMETHOBENZAMIDE 300 MG CAP, is $1.2941 per EA — about 93% below TRIMETHOBENZAMIDE 300 MG CAP.
Who manufactures TRIMETHOBENZAMIDE 300 MG CAP?
TRIMETHOBENZAMIDE 300 MG CAP (NDC 62135077330) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.